Pharmaceutical giant Sanofi (NASDAQ:SNY) and biotech Regeneron (NASDAQ:REGN) have announced the start of two late-stage clinical trials for their experimental rheumatoid arthritis drug sarilumab. This antibody is being tested in combination with methotrexate, a drug often used for the treatment of rheumatoid arthritis, and will be compared to Amgen (NASDAQ:AMGN) and Pfizer's (NYSE:PFE) Enbrel. In the following video, health-care analyst Max Macaluso discusses these clinical trials and how this drug could compete in the rheumatoid arthritis market.
- May 15, 2013 at 9:13PM
- Health Care